Format

Send to

Choose Destination
Cell Death Dis. 2018 Jan 25;9(2):109. doi: 10.1038/s41419-017-0152-y.

Regulatory B cells: the cutting edge of immune tolerance in kidney transplantation.

Author information

1
Transplantation Center, The Third Xiangya Hospital, Central South University, Changsha Hunan, 410013, P. R. China.
2
Transplantation Center, The Third Xiangya Hospital, Central South University, Changsha Hunan, 410013, P. R. China. myz_china@aliyun.com.
3
Department of Urology, Zhongshan Hospital; Shanghai Key Laboratory of Organ Transplantation, Fudan University, Shanghai, 200032, P. R. China. esuperyc@163.com.

Abstract

Kidney transplantation is the optimal treatment for end-stage renal diseases. Although great improvement has been achieved, immune tolerance is still the Holy Grail that every organ transplant practitioner pursues. The role of B cells in transplantation has long been considered simply to serve as precursors of plasma cells, which produce alloantibodies and induce antibody-mediated rejection. Recent research indicates that a specialized subset of B cells plays an important role in immune regulation, which has been well demonstrated in autoimmune diseases, infections, and cancers. This category of regulatory B cells (Bregs) differs from conventional B cells, and they may help develop a novel immunomodulatory therapeutic strategy to achieve immune tolerance in transplantation. Here, we review the latest evidence regarding phenotypes, functions, and effectors of Bregs and discuss their diverse effects on kidney transplantation.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center